DEALS
Zhong Lun Advises Innovative Biotechnology Company Virax Biolabs on its IPO and Listing on Nasdaq
Zhong Lun Advises Innovative Biotechnology Company Virax Biolabs on its IPO and Listing on Nasdaq
On July 21, 2022, Virax Biolabs Group Limited (“Virax") (Nasdaq: VRAX) completed its IPO and got listed on the Nasdaq Capital Market. The IPO consisted of a fresh issue of 1,350,000 ordinary shares at a price of US$5.00 per share, raising a total of US$6.75 million.
Virax is an innovative biotechnology company incorporated in Cayman Islands and focusing on the prevention, detection, and diagnosis of viral diseases. Its product portfolio includes diagnostics test kits, diagnostic medical devices, and PPE products.
Zhong Lun acted as the PRC legal counsel for Virax in connection with the global offering and listing on Nasdaq. The legal team was led by partners Wayne Wang and Chunlan Liao and included associates Joice Chen and Nina Liu.
